$SER
Serina Therapeutics Inc Stock $ser

$ser Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000149315224030988 Filed on August 09, 2024

Income Statement

Concept	2024 Q3	2024 Q2	2023 Q2
Revenue	$14.00K	$51.00K	$9.000K
YoY Change	-79.1%	466.67%	-25.0%
Cost Of Revenue			$5.000K
YoY Change			-16.67%
Gross Profit			$4.000K
YoY Change			-33.33%
Gross Profit Margin			44.44%
Selling, General & Admin		$2.323M	$1.730M
YoY Change		34.28%	29.3%
% of Gross Profit			43250.0%
Research & Development	$2.415M	$1.594M	$160.0K
YoY Change	1007.8%	896.25%	-38.22%
% of Gross Profit			4000.0%
Depreciation & Amortization		$24.00K	$32.00K
YoY Change		-25.0%	-3.03%
% of Gross Profit			800.0%
Operating Expenses	$5.326M	$3.917M	$1.890M
YoY Change	122.85%	107.25%	18.35%
Operating Profit	-$5.312M	-$3.866M	-$1.886M
YoY Change	125.47%	104.98%	18.54%
Interest Expense		$9.052M	$792.0K
YoY Change		1042.93%	-191.77%
% of Operating Profit
Other Income/Expense, Net	$6.695M	$9.043M	-$793.0K
YoY Change	-320.74%	-1240.35%	-22.78%
Pretax Income		$5.177M	-$2.679M
YoY Change		-293.24%	2.33%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	$1.410M	$5.204M	-$2.669M
YoY Change	-126.11%	-294.98%	1.95%
Net Earnings / Revenue	10071.43%	10203.92%	-29655.56%
Basic Earnings Per Share	$0.16	$0.61	-$0.07
Diluted Earnings Per Share	$0.13	$0.51	-$0.07
COMMON SHARES
Basic Shares Outstanding	8.881M shares	8.414M shares	37.95M shares
Diluted Shares Outstanding	10.75M shares	10.16K shares	37.95K shares

Balance Sheet

Concept	2024 Q3	2024 Q2	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments		$6.064M	$261.0K
YoY Change		2223.37%	-62.82%
Cash & Equivalents	$3.185M	$6.064M	$261.0K
Short-Term Investments
Other Short-Term Assets	$143.0K	$2.000K	$1.083M
YoY Change	-78.66%	-99.82%	7.12%
Inventory
Prepaid Expenses
Receivables			$6.000K
Other Receivables			$0.00
Total Short-Term Assets	$5.423M	$8.917M	$1.350M
YoY Change	375.28%	560.52%	-21.74%
LONG-TERM ASSETS
Property, Plant & Equipment	$519.0K	$540.0K
YoY Change
Goodwill
YoY Change
Intangibles	$509.0K	$541.0K	$673.0K
YoY Change	-20.47%	-19.61%	-16.29%
Long-Term Investments
YoY Change
Other Assets		$50.00K	$50.00K
YoY Change		0.0%	0.0%
Total Long-Term Assets	$2.012M	$1.791M	$10.93M
YoY Change	-81.82%	-83.61%	1179.51%
TOTAL ASSETS
Total Short-Term Assets	$5.423M	$8.917M	$1.350M
Total Long-Term Assets	$2.012M	$1.791M	$10.93M
Total Assets	$7.435M	$10.71M	$12.28M
YoY Change	-39.11%	-12.78%	376.04%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$1.203M	$506.0K
YoY Change		137.75%	214.29%
Accrued Expenses	$1.159M	$320.0K	$256.0K
YoY Change	295.56%	25.0%	-50.86%
Deferred Revenue
YoY Change
Short-Term Debt		$0.00	$0.00
YoY Change
Long-Term Debt Due		$10.46M	$22.94M
YoY Change		-54.43%	229.26%
Total Short-Term Liabilities	$13.51M	$12.63M	$24.51M
YoY Change	321.79%	-48.45%	169.73%
LONG-TERM LIABILITIES
Long-Term Debt		$693.0K	$10.07M
YoY Change		-93.12%	49.02%
Other Long-Term Liabilities		$13.78M
YoY Change
Total Long-Term Liabilities		$14.47M	$10.07M
YoY Change		43.7%	49.02%
TOTAL LIABILITIES
Total Short-Term Liabilities	$13.51M	$12.63M	$24.51M
Total Long-Term Liabilities		$14.47M	$10.07M
Total Liabilities	$21.26M	$27.10M	$34.57M
YoY Change	445.62%	-21.61%	118.25%
SHAREHOLDERS EQUITY
Retained Earnings	-$21.78M	-$23.19M	-$122.2M
YoY Change	-82.93%	-81.03%	10.02%
Common Stock	$1.000K	$1.000K	$4.000K
YoY Change	-75.0%	-75.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$13.77M	-$16.36M	-$22.18M
YoY Change
Total Liabilities & Shareholders Equity	$7.435M	$10.71M	$12.28M
YoY Change	-39.11%	-12.78%	376.04%

Cashflow Statement

Concept	2024 Q3	2024 Q2	2023 Q2
OPERATING ACTIVITIES
Net Income	$1.410M	$5.204M	-$2.669M
YoY Change	-126.11%	-294.98%	1.95%
Depreciation, Depletion And Amortization		$24.00K	$32.00K
YoY Change		-25.0%	-3.03%
Cash From Operating Activities		-$8.009M	-$2.019M
YoY Change		296.68%	15.64%
INVESTING ACTIVITIES
Capital Expenditures		$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities			$0.00
YoY Change
Cash From Investing Activities		$0.00	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		5.367M	2.000M
YoY Change		168.35%	0.0%
NET CHANGE
Cash From Operating Activities		-8.009M	-2.019M
Cash From Investing Activities		0.000	0.000
Cash From Financing Activities		5.367M	2.000M
Net Change In Cash		-2.642M	-19.00K
YoY Change		13805.26%	-107.48%
FREE CASH FLOW
Cash From Operating Activities		-$8.009M	-$2.019M
Capital Expenditures		$0.00
Free Cash Flow		-$8.009M
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	1-38519
	dei	Entity Registrant Name EntityRegistrantName	Serina Therapeutics, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-1436829
	dei	Entity Address Address Line1 EntityAddressAddressLine1	601 Genome Way
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 2001
	dei	Entity Address City Or Town EntityAddressCityOrTown	Huntsville
	dei	Entity Address State Or Province EntityAddressStateOrProvince	AL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	35806
	dei	City Area Code CityAreaCode	(256)
	dei	Local Phone Number LocalPhoneNumber	327-9630
	dei	Trading Symbol TradingSymbol	SER
	dei	Security Exchange Name SecurityExchangeName	NYSE
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	37000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3543000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1066000	usd
CY2024Q2	us-gaap	Operating Expenses OperatingExpenses	3917000	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	952000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-945000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-6187000	usd
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Central Index Key EntityCentralIndexKey	0001708599
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	8881426	shares
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6064000	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	8917000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	540000	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	562000	usd
CY2024Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	98000	usd
CY2024Q2	us-gaap	Assets Assets	10708000	usd
CY2024Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1972000	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	362000	usd
CY2024Q2	us-gaap	Liabilities Liabilities	27101000	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q4	us-gaap	Grants Receivable Current GrantsReceivableCurrent		usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent		usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent		usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill		usd
CY2023Q4	us-gaap	Loans Payable Current LoansPayableCurrent		usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent		usd
CY2023Q4	SER	Warrant Liability WarrantLiability		usd
CY2023Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable		usd
CY2024Q2	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent		usd
CY2024Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent		usd
CY2024Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q2	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest		usd
CY2024Q2	SER	Fairvalue Inception Adjustment On Convertible Promissory Note FairvalueInceptionAdjustmentOnConvertiblePromissoryNote		usd
CY2023Q2	SER	Fairvalue Inception Adjustment On Convertible Promissory Note FairvalueInceptionAdjustmentOnConvertiblePromissoryNote		usd
	SER	Fairvalue Inception Adjustment On Convertible Promissory Note FairvalueInceptionAdjustmentOnConvertiblePromissoryNote		usd
CY2024Q2	SER	Change In Fair Value Of Convertible Promissory Notes ChangeInFairValueOfConvertiblePromissoryNotes		usd
CY2023Q2	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense		usd
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense		usd
CY2023Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest		usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest		usd
CY2024Q2	SER	Noncontrolling Interest Adjustments To Additional Paid In Capital Transactions With Noncontrolling Interests NoncontrollingInterestAdjustmentsToAdditionalPaidInCapitalTransactionsWithNoncontrollingInterests		usd
	SER	Noncontrolling Interest Adjustments To Additional Paid In Capital Transactions With Noncontrolling Interests NoncontrollingInterestAdjustmentsToAdditionalPaidInCapitalTransactionsWithNoncontrollingInterests		usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest		usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts		usd
	SER	Fairvalue Inception Adjustment On Convertible Promissory Note FairvalueInceptionAdjustmentOnConvertiblePromissoryNote		usd
	SER	Increase Decrease In Grant Receivables IncreaseDecreaseInGrantReceivables		usd
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties		usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities		usd
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit		usd
	SER	Cash And Restricted Cash Acquired In Connection With Merger CashAndRestrictedCashAcquiredInConnectionWithMerger		usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
	us-gaap	Repayments Of Longterm Loans From Vendors RepaymentsOfLongtermLoansFromVendors		usd
	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired		usd
	us-gaap	Stock Issued1 StockIssued1		usd
	us-gaap	Notes Issued1 NotesIssued1		usd
	SER	Merger And Issuance Of Common Stock Upon Consummation Of Merger MergerAndIssuanceOfCommonStockUponConsummationOfMerger		usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital		usd
CY2023Q4	us-gaap	Restricted Cash Equivalents RestrictedCashEquivalents		usd
CY2023Q4	SER	Prepaid Technology Access Fee PrepaidTechnologyAccessFee		usd
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent		usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent		usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent		usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
CY2023Q2	us-gaap	Accelerated Share Repurchases Final Price Paid Per Share AcceleratedShareRepurchasesFinalPricePaidPerShare
	us-gaap	Accelerated Share Repurchases Final Price Paid Per Share AcceleratedShareRepurchasesFinalPricePaidPerShare
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate		pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate		pure
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate		pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate		pure
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability		usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability		usd
CY2024Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent		usd
CY2024Q2	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo		usd
CY2024Q2	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree		usd
CY2024Q2	SER	Finance Lease Liability Payments Due After Year Three FinanceLeaseLiabilityPaymentsDueAfterYearThree		usd
CY2024Q2	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount		usd
CY2024Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent		usd
CY2023Q2	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic		usd
	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic		usd
CY2024Q2	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax		usd
	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax		usd
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements		shares
CY2024Q2	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants		shares
CY2023Q2	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants		shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants		shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants		shares
CY2024Q2	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities		shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities		shares
CY2024Q2	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock		shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock		shares
	dei	Document Type DocumentType	10-Q
	dei	Entity Listing Par Value Per Share EntityListingParValuePerShare	0.0001
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7619000	usd
CY2024Q2	us-gaap	Grants Receivable Current GrantsReceivableCurrent	51000	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2802000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	7619000	usd
CY2024Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	50000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	573000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	666000	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	110000	usd
CY2024Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	541000	usd
CY2023Q4	us-gaap	Assets Assets	8968000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1163000	usd
CY2024Q2	us-gaap	Loans Payable Current LoansPayableCurrent	10445000	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	200000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	214000	usd
CY2024Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	11000	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	36000	usd
CY2024Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	5000	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	12633000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1413000	usd
CY2024Q2	SER	Warrant Liability WarrantLiability	13413000	usd
CY2024Q2	us-gaap	Long Term Loans Payable LongTermLoansPayable	693000	usd
CY2023Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	2983000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	461000	usd
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	1000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	4858000	usd
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2024Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	40000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	40000000	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8792000	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8792000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2410000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2410000	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	1000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	25000	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	6821000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	858000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-23185000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-33177000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-16363000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-32294000	usd
CY2024Q2	us-gaap	Minority Interest MinorityInterest	-30000	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-16393000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-32294000	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	10708000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8968000	usd
CY2024Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	51000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	56000	usd
CY2024Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1594000	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	479000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2700000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	878000	usd
CY2024Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2323000	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	473000	usd
	us-gaap	Operating Expenses OperatingExpenses	6243000	usd
	us-gaap	Operating Expenses OperatingExpenses	1944000	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-3866000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1907000	usd
CY2024Q2	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	242000	usd
CY2023Q2	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	108000	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	341000	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	194000	usd
	SER	Fairvalue Inception Adjustment On Convertible Promissory Note FairvalueInceptionAdjustmentOnConvertiblePromissoryNote	2240000	usd
CY2023Q2	SER	Change In Fair Value Of Convertible Promissory Notes ChangeInFairValueOfConvertiblePromissoryNotes	-1570000	usd
	SER	Change In Fair Value Of Convertible Promissory Notes ChangeInFairValueOfConvertiblePromissoryNotes	7017000	usd
	SER	Change In Fair Value Of Convertible Promissory Notes ChangeInFairValueOfConvertiblePromissoryNotes	-1864000	usd
CY2024Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-9294000	usd
CY2023Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-291000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-3716000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-463000	usd
CY2024Q2	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	9000	usd
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	9000	usd
CY2024Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	9043000	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1753000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3651000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4373000	usd
CY2024Q2	us-gaap	Profit Loss ProfitLoss	5177000	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	808000	usd
	us-gaap	Profit Loss ProfitLoss	-9838000	usd
	us-gaap	Profit Loss ProfitLoss	2466000	usd
CY2024Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-27000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-27000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	5204000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	808000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9811000	usd
	us-gaap	Net Income Loss NetIncomeLoss	2466000	usd
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.61
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.37
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.74
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.14
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.51
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.11
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.74
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.34
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8514	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2172	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5652	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2170	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	10157	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7434	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5652	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7427	shares
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-28388000	usd
CY2024Q2	SER	Stock Issued During Period Value Warrant Exercised StockIssuedDuringPeriodValueWarrantExercised	6360000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	458000	usd
CY2024Q2	us-gaap	Profit Loss ProfitLoss	5177000	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-16393000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-36118000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	23000	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	808000	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-35286000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-32294000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	36404000	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	10721000	usd
	SER	Stock Issued During Period Value Warrant Exercised StockIssuedDuringPeriodValueWarrantExercised	6360000	usd
	SER	Stock Issued During Period Value Cancellation Of Common Stock Upon Consummation Of Merger StockIssuedDuringPeriodValueCancellationOfCommonStockUponConsummationOfMerger	-10721000	usd
	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	-18501000	usd
	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	961000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	511000	usd
	us-gaap	Profit Loss ProfitLoss	-9838000	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-16393000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-37778000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-37778000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	25000	usd
	us-gaap	Profit Loss ProfitLoss	2466000	usd
	us-gaap	Profit Loss ProfitLoss	2466000	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-35286000	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-35286000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9811000	usd
	us-gaap	Net Income Loss NetIncomeLoss	2466000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-27000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	82000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	30000	usd
	SER	Noncash Lease Expense NoncashLeaseExpense	116000	usd
	SER	Noncash Lease Expense NoncashLeaseExpense	90000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	329000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	511000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	25000	usd
	SER	Fairvalue Inception Adjustment On Convertible Promissory Note FairvalueInceptionAdjustmentOnConvertiblePromissoryNote	2240000	usd
	SER	Change In Fair Value Of Convertible Promissory Note ChangeInFairValueOfConvertiblePromissoryNote	-7017000	usd
	SER	Change In Fair Value Of Convertible Promissory Note ChangeInFairValueOfConvertiblePromissoryNote	1864000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-3716000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-463000	usd
	SER	Increase Decrease In Grant Receivables IncreaseDecreaseInGrantReceivables	-15000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2694000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1398000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	185000	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-163000	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-282000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-112000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-85000	usd
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-66000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	5000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9586000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1573000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	14000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	315000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-14000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-315000	usd
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	2925000	usd
	SER	Cash And Restricted Cash Acquired In Connection With Merger CashAndRestrictedCashAcquiredInConnectionWithMerger	337000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1000	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	4988000	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	10100000	usd
	us-gaap	Repayments Of Longterm Loans From Vendors RepaymentsOfLongtermLoansFromVendors	133000	usd
	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	26000	usd
	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	23000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8095000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10078000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1505000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	8190000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	7619000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	532000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6114000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8722000	usd
	us-gaap	Interest Paid Net InterestPaidNet	2000	usd
	us-gaap	Interest Paid Net InterestPaidNet	4000	usd
	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	497000	usd
	us-gaap	Stock Issued1 StockIssued1	36404000	usd
	us-gaap	Notes Issued1 NotesIssued1	10721000	usd
	SER	Merger And Issuance Of Common Stock Upon Consummation Of Merger MergerAndIssuanceOfCommonStockUponConsummationOfMerger	961000	usd
	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	0.97682654	shares
	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	5913277	shares
	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	0.97682654	shares
	us-gaap	Net Income Loss NetIncomeLoss	-9800000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9600000	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6100000	usd
	SER	Expected Proceeds From Warrant Exercises ExpectedProceedsFromWarrantExercises	10000000	usd
CY2024Q1	SER	Warrant Liability WarrantLiability	24079000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-28389000	usd
CY2024Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-5578000	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.38
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.38
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_847_eus-gaap--UseOfEstimates_zewjZnX9c9I8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_869_zjxrcW6wFQYc">Use of estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and (ii) the reported amounts of revenues and expenses during the reporting period, in each case with consideration given to materiality. Significant estimates and assumptions which are subject to significant judgment include those related to going concern assessment of consolidated financial statements, useful lives associated with long-lived assets, including evaluation of asset impairment, allowances for uncollectible accounts receivables, loss contingencies, deferred income taxes and tax reserves, including valuation allowances related to deferred income taxes, determining the fair value of the Company’s embedded derivatives in the convertible notes payable and receivable, and assumptions used to value stock-based awards or other equity instruments and liability classified warrants. Actual results could differ materially from those estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_846_eus-gaap--ConcentrationRiskCreditRisk_zmICfUqfKHJ2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_zgKh69UaSPT7">Concentration of credit risk and other risks and uncertainties</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of risk consist principally of cash equivalents. The Company maintains its cash deposits in Federal Deposit Insurance Corporation (“FDIC”) insured financial institutions and may at times hold investments at Securities Investor Protection Corporation (“SIPC”) insured broker-dealers.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At times, the balances in these accounts may be in excess of FDIC and SIPC insured limits. At June 30, 2024 and December 31, 2023, cash and cash equivalents deposits in excess of FDIC limits were approximately $<span id="xdx_90C_eus-gaap--CashFDICInsuredAmount_iI_pn5n6_c20240630_zlC9udB8G4B3" title="Cash, FDIC insured amount">1.3</span> million and $<span id="xdx_901_eus-gaap--CashFDICInsuredAmount_iI_c20231231_zJpFM1XXhMPj" title="Cash, FDIC insured amount">0</span>, respectively, and investments and deposits in excess of SIPC limits were $<span id="xdx_90D_ecustom--CashExcessOfSIPCInsuredLimits_iI_pn5n6_c20240630_zlrX6CssjcId" title="Cash, SIPC insured amount">4.3</span> million and $<span id="xdx_90D_ecustom--CashExcessOfSIPCInsuredLimits_iI_pn5n6_c20231231_zvLHHY9ins26" title="Cash, SIPC insured amount">7.3</span> million, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grant revenues for the periods presented are related to grants from the National Institutes of Health (“NIH”). See Note 4, <i>Grant Revenues,</i> for further discussion on grant awards.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product candidates developed by the Company and its subsidiaries will require approvals or clearances from the United States Food and Drug Administration (“FDA”) or foreign regulatory agencies prior to commercial sales. There can be no assurance that any of the product candidates being developed or planned to be developed by the Company or its subsidiaries will receive any of the required approvals or clearances. If regulatory approval or clearance were to be denied or any such approval or clearance was to be delayed, it would have a material adverse impact on the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p>
CY2024Q2	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	1300000	usd
CY2023Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	0	usd
CY2024Q2	SER	Cash Excess Of Sipc Insured Limits CashExcessOfSIPCInsuredLimits	4300000	usd
CY2023Q4	SER	Cash Excess Of Sipc Insured Limits CashExcessOfSIPCInsuredLimits	7300000	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6064000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7619000	usd
CY2024Q2	us-gaap	Restricted Cash Equivalents RestrictedCashEquivalents	50000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6114000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	7619000	usd
	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	(i) 75% or greater to determine whether the lease term is a major part of the remaining economic life of the underlying asset and (ii) 90% or greater to determine whether the present value of the sum of lease payments is substantially all of the fair value of the underlying asset.
CY2024Q2	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P10Y
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_84D_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zGN5gVhh38k2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_868_z6s8PaL45TY8">Reclassifications</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain reclassifications have been made to the prior period condensed consolidated interim financial statements to conform to current year presentation of the <i>Accounts payable and accrued liabilities </i>amount in the condensed consolidated balance sheet.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q2	SER	Prepaid Technology Access Fee PrepaidTechnologyAccessFee	2000000	usd
CY2024Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	800000	usd
CY2024Q2	us-gaap	Other Assets Current OtherAssetsCurrent	2000	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2802000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	977000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	963000	usd
CY2024Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	437000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	390000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	540000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	573000	usd
CY2024Q2	us-gaap	Depreciation Depreciation	24000	usd
CY2023Q2	us-gaap	Depreciation Depreciation	18000	usd
	us-gaap	Depreciation Depreciation	47000	usd
	us-gaap	Depreciation Depreciation	31000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	576000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	35000	usd
CY2024Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	541000	usd
CY2024Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	33000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	35000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	65000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	131000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	132000	usd
CY2024Q2	SER	Finite Lived Intangible Assets Amortization Expense After Year Two FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearTwo	213000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	541000	usd
CY2024Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1203000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	580000	usd
CY2024Q2	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	449000	usd
CY2023Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	13000	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	320000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	570000	usd
CY2024Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1972000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1163000	usd
CY2023Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	53980	shares
CY2024Q1	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1 for 35.17
CY2024Q2	us-gaap	Common Stock Held By Subsidiary CommonStockHeldBySubsidiary	250000	usd
CY2024Q2	SER	Warrant Liabilities Fair Value Disclosures WarrantLiabilitiesFairValueDisclosures	13413000	usd
CY2024Q2	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	13413000	usd
CY2023Q4	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	2983000	usd
CY2023Q4	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	2983000	usd
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q2	us-gaap	Preferred Stock Convertible Shares Issuable PreferredStockConvertibleSharesIssuable	5913277	shares
CY2023Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	4918	shares
CY2023Q4	SER	Temporary Equity Shares Issued And Outstanding TemporaryEquitySharesIssuedAndOutstanding	3438	shares
CY2023Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	36404	usd
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	40000000	shares
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
	us-gaap	Common Stock Voting Rights CommonStockVotingRights	common stock are entitled to one vote for each share
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8791754	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8791754	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2410255	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2410255	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	358511	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	20.47
CY2023Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	358511	shares
CY2023Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	20.47
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	473681	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	20.47
CY2024Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	473681	shares
CY2024Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	20.47
CY2024Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	458000	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	22000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	511000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	24000	usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	11.31
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	11.72
CY2024Q2	us-gaap	Accelerated Share Repurchases Final Price Paid Per Share AcceleratedShareRepurchasesFinalPricePaidPerShare	11.31
	us-gaap	Accelerated Share Repurchases Final Price Paid Per Share AcceleratedShareRepurchasesFinalPricePaidPerShare	11.72
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y10M24D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y10M17D
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.1805	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.1803	pure
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0451	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0447	pure
CY2024Q2	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	0	usd
	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	0	usd
CY2023Q2	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	0	usd
	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	0	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	112000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	85000	usd
	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	2000	usd
	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	4000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	26000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	23000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	497000	usd
CY2024Q2	SER	Operating Lease Right Of Use Asset Before Accumulated Amortization OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization	862000	usd
CY2023Q4	SER	Operating Lease Right Of Use Asset Before Accumulated Amortization OperatingLeaseRightOfUseAssetBeforeAccumulatedAmortization	862000	usd
CY2024Q2	SER	Operating Lease Right Of Use Asset Accumulated Amortization OperatingLeaseRightOfUseAssetAccumulatedAmortization	300000	usd
CY2023Q4	SER	Operating Lease Right Of Use Asset Accumulated Amortization OperatingLeaseRightOfUseAssetAccumulatedAmortization	196000	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	562000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	666000	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	200000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	214000	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	362000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	461000	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	562000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	675000	usd
CY2024Q2	us-gaap	Finance Lease Right Of Use Asset Before Accumulated Amortization FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization	163000	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset Before Accumulated Amortization FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization	163000	usd
CY2024Q2	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	65000	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	53000	usd
CY2024Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	98000	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	110000	usd
CY2024Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	11000	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	36000	usd
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	1000	usd
CY2024Q2	us-gaap	Finance Lease Liability FinanceLeaseLiability	11000	usd
CY2023Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	37000	usd
CY2024Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y11M15D
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y3M25D
CY2024Q2	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P0Y3M14D
CY2023Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P0Y7M20D
CY2024Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0667	pure
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0667	pure
CY2024Q2	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.119	pure
CY2023Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.119	pure
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	113000	usd
CY2024Q2	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	10000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	217000	usd
CY2024Q2	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	1000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	159000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	117000	usd
CY2024Q2	SER	Lessee Operating Lease Liability Payments Due After Year Three LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree	10000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	616000	usd
CY2024Q2	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	11000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	54000	usd
CY2024Q2	SER	Lessee Operating Lease Total Obligations LesseeOperatingLeaseTotalObligations	562000	usd
CY2024Q2	SER	Finance Lease Total Obligations FinanceLeaseTotalObligations	11000	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	200000	usd
CY2024Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	11000	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	362000	usd
CY2024Q2	us-gaap	Profit Loss ProfitLoss	5177000	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	808000	usd
	us-gaap	Profit Loss ProfitLoss	-9838000	usd
	us-gaap	Profit Loss ProfitLoss	2466000	usd
CY2024Q2	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	27000	usd
	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	27000	usd
CY2024Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	5204000	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	808000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9811000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	2466000	usd
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8514	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2172	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5652	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2170	shares
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.61
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.37
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.74
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.14
CY2024Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	5204000	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	808000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9811000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	2466000	usd
CY2023Q2	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	22000	usd
	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	76000	usd
CY2024Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	5204000	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	830000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-9811000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	2542000	usd
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8514	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2172	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5652	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2170	shares
CY2024Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1643000	shares
CY2023Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1823000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1820000	shares
CY2023Q2	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	115000	shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	113000	shares
CY2023Q2	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	3324000	shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	3324000	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	10157	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7434	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5652	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7427	shares
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.51
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.11
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.74
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.34
CY2024Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3878000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5530000	shares
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001493152-24-030988-index-headers.html	Edgar Link	pending
0001493152-24-030988-index.html	Edgar Link	pending
0001493152-24-030988.txt	Edgar Link	pending
0001493152-24-030988-xbrl.zip	Edgar Link	pending
ex31.htm	Edgar Link	pending
ex32.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
ser-20240630.xsd	Edgar Link	pending
Show.js	Edgar Link	pending
ser-20240630_cal.xml	Edgar Link	unprocessable
ser-20240630_def.xml	Edgar Link	unprocessable
ser-20240630_lab.xml	Edgar Link	unprocessable
ser-20240630_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SER
Serina Therapeutics Inc Stock $ser

2024 Q3 Form 10-Q Financial Statement

#000149315224030988 Filed on August 09, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SER Serina Therapeutics Inc Stock $ser

2024 Q3 Form 10-Q Financial Statement

#000149315224030988 Filed on August 09, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SER
Serina Therapeutics Inc Stock $ser